{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T07:34:51Z","timestamp":1779262491795,"version":"3.51.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,1,16]],"date-time":"2008-01-16T00:00:00Z","timestamp":1200441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1038\/ncprheum0708","type":"journal-article","created":{"date-parts":[[2008,1,16]],"date-time":"2008-01-16T17:30:52Z","timestamp":1200504652000},"page":"136-144","source":"Crossref","is-referenced-by-count":42,"title":["Drug Insight: autoimmune effects of medications\u2014what's new?"],"prefix":"10.1038","volume":"4","author":[{"given":"Anne-Barbara","family":"Mongey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn V","family":"Hess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,1,16]]},"reference":[{"key":"BFncprheum0708_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/art.1780350216","volume":"35","author":"AB Mongey","year":"1992","unstructured":"Mongey AB et al. (1992) Serologic evaluation of patients receiving procainamide. Arthritis Rheum 35: 219\u2013223","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0708_CR2","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1172\/JCI115353","volume":"88","author":"RW Burlingame","year":"1991","unstructured":"Burlingame RW and Rubin RL (1991) Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin. J Clin Invest 88: 680\u2013690","journal-title":"J Clin Invest"},{"key":"BFncprheum0708_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7326\/0003-4819-108-3-369","volume":"108","author":"MG Cohen","year":"1988","unstructured":"Cohen MG et al. (1988) Two distinct quinidine-induced rheumatic syndromes. Ann Intern Med 108: 369\u2013371","journal-title":"Ann Intern Med"},{"key":"BFncprheum0708_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1172\/JCI115832","volume":"90","author":"RL Rubin","year":"1992","unstructured":"Rubin RL et al. (1992) Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex. J Clin Invest 90: 165\u2013173","journal-title":"J Clin Invest"},{"key":"BFncprheum0708_CR5","first-page":"2157","volume":"21","author":"VJ Bray","year":"1994","unstructured":"Bray VJ et al. (1994) Antihistone autoantibody profile in sulfasalazine induced lupus. J Rheumatol 21: 2157\u20132158","journal-title":"J Rheumatol"},{"key":"BFncprheum0708_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.semarthrit.2004.07.002","volume":"34","author":"Y Sherer","year":"2004","unstructured":"Sherer Y et al. (2004) Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 34: 501\u2013537","journal-title":"Semin Arthritis Rheum"},{"key":"BFncprheum0708_CR7","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S0002-9343(98)00325-8","volume":"105","author":"O Elkayam","year":"1998","unstructured":"Elkayam O et al. (1998) Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena. Am J Med 105: 484\u2013487","journal-title":"Am J Med"},{"key":"BFncprheum0708_CR8","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1191\/096120399678841025","volume":"8","author":"C Tournigand","year":"1999","unstructured":"Tournigand C et al. (1999) Minocycline-induced clinical and biological lupus-like disease. Lupus 8: 773\u2013774","journal-title":"Lupus"},{"key":"BFncprheum0708_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/bmj.312.7024.169","volume":"312","author":"A Gough","year":"1996","unstructured":"Gough A et al. (1996) Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 312: 169\u2013172","journal-title":"BMJ"},{"key":"BFncprheum0708_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/rheumatology\/40.3.329","volume":"40","author":"TM Lawson","year":"2001","unstructured":"Lawson TM et al. (2001) Minocycline induced lupus: clinical features and response to rechallenge. Rheumatology (Oxford) 40: 329\u2013335","journal-title":"Rheumatology (Oxford)"},{"key":"BFncprheum0708_CR11","first-page":"1004","volume":"28","author":"MM Gordon","year":"2001","unstructured":"Gordon MM and Porter D (2001) Minocycline related lupus: case series in the West of Scotland. J Rheumatol 28: 1004\u20131006","journal-title":"J Rheumatol"},{"key":"BFncprheum0708_CR12","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/ard.55.10.769","volume":"55","author":"O Elkayam","year":"1996","unstructured":"Elkayam O et al. (1996) Minocycline induced arthritis associated with fever, livedo reticularis and pANCA. Ann Rheum Dis 55: 769\u2013771","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0708_CR13","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/archderm.1996.03890320082013","volume":"132","author":"SR Knowles","year":"1996","unstructured":"Knowles SR et al. (1996) Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Arch Dermatol 132: 934\u2013939","journal-title":"Arch Dermatol"},{"key":"BFncprheum0708_CR14","first-page":"587","volume":"16","author":"S Knights","year":"1998","unstructured":"Knights S et al. (1998) Minocycline-induced arthritis. Clin Exp Rheumatol 16: 587\u2013590","journal-title":"Clin Exp Rheumatol"},{"key":"BFncprheum0708_CR15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/archinte.159.5.493","volume":"159","author":"MC Sturkenboom","year":"1999","unstructured":"Sturkenboom MC et al. (1999) Minocycline and lupuslike syndrome in acne patients. Arch Intern Med 159: 493\u2013497","journal-title":"Arch Intern Med"},{"key":"BFncprheum0708_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1046\/j.1365-2133.2000.03357.x","volume":"142","author":"J Dunphy","year":"2000","unstructured":"Dunphy J et al. (2000) Anti-neutrophil cytoplasmic antibodies and HLA class II alleles in minocyline-induced lupus like-syndrome. Br J Dermatol 142: 461\u2013467","journal-title":"Br J Dermatol"},{"key":"BFncprheum0708_CR17","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/rheumatology\/39.8.886","volume":"39","author":"I Gunnarrson","year":"2000","unstructured":"Gunnarrson I et al. (2000) Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment\u2014the role of IL-10 and HLA. Rheumatology (Oxford) 39: 886\u2013893","journal-title":"Rheumatology (Oxford)"},{"key":"BFncprheum0708_CR18","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/ard.58.5.288","volume":"58","author":"M-M Gordon","year":"1999","unstructured":"Gordon M-M et al. (1999) Does sulphasalazine cause drug-induced lupus erythematosus? No effect evident in a prospective randomized trial of 200 rheumatoid patients treated with sulfasalazine or auranofin over five years. Ann Rheum Dis 58: 288\u2013290","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0708_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1468-3083.2006.01838.x","volume":"21","author":"B No\u00ebl","year":"2007","unstructured":"No\u00ebl B (2007) Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 21: 17\u201324","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"BFncprheum0708_CR20","unstructured":"Kaur H et al. (2001) Simvastatin-induced lupus erythematosus. Presented at the ACP-ASIM Ohio Chapter Scientific Meeting: 2001 October 12\u201313, Cleveland, OH"},{"key":"BFncprheum0708_CR21","first-page":"S121","volume":"10","author":"GE Obermoser","year":"2001","unstructured":"Obermoser GE et al. (2001) Lupus-like syndrome associated with Atorvastatin. Lupus 10: S121","journal-title":"Lupus"},{"key":"BFncprheum0708_CR22","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.2165\/00003495-200262150-00002","volume":"62","author":"LJ Raggatt","year":"2002","unstructured":"Raggatt LJ and Partridge NC (2002) HMG-CoA reductase inhibitors as immunomodulators: potential use in transplant rejection. Drugs 62: 2185\u20132191","journal-title":"Drugs"},{"key":"BFncprheum0708_CR23","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","volume":"359","author":"M Baum","year":"2002","unstructured":"Baum M et al. (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359: 2131\u20132139","journal-title":"Lancet"},{"key":"BFncprheum0708_CR24","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa032312","volume":"349","author":"PE Goss","year":"2003","unstructured":"Goss PE et al. (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1793\u20131802","journal-title":"N Engl J Med"},{"key":"BFncprheum0708_CR25","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1056\/NEJMoa040331","volume":"350","author":"RC Coombes","year":"2004","unstructured":"Coombes RC et al. (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081\u20131092","journal-title":"N Engl J Med"},{"key":"BFncprheum0708_CR26","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1200\/JCO.2001.19.10.2767","volume":"19","author":"PP Donnellan","year":"2001","unstructured":"Donnellan PP et al. (2001) Aromatase inhibitors and arthralgia [letter]. J Clin Oncol 19: 2767","journal-title":"J Clin Oncol"},{"key":"BFncprheum0708_CR27","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1200\/JCO.2000.18.22.3748","volume":"18","author":"J Bonneterre","year":"2000","unstructured":"Bonneterre J et al. (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18: 3748\u20133757","journal-title":"J Clin Oncol"},{"key":"BFncprheum0708_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.1998.16.2.453","volume":"16","author":"P Dombernowsky","year":"1998","unstructured":"Dombernowsky P et al. (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: 453\u2013461","journal-title":"J Clin Oncol"},{"key":"BFncprheum0708_CR29","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.2165\/00003495-200059060-00010","volume":"59","author":"A Markham","year":"2000","unstructured":"Markham A and Lamb HM (2000) Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 59: 1341\u20131359","journal-title":"Drugs"},{"key":"BFncprheum0708_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0016-5085(03)00701-7","volume":"125","author":"S Vermeire","year":"2003","unstructured":"Vermeire S et al. (2003) Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 125: 32\u201339","journal-title":"Gastroenterology"},{"key":"BFncprheum0708_CR31","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","volume":"43","author":"PJ Charles","year":"2000","unstructured":"Charles PJ et al. (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43: 2383\u20132390","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0708_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/08916930400021378","volume":"38","author":"O Elkayam","year":"2005","unstructured":"Elkayam O et al. (2005) Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. Autoimmunity 38: 155\u2013160","journal-title":"Autoimmunity"},{"key":"BFncprheum0708_CR33","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/art.10876","volume":"48","author":"L De Rycke","year":"2003","unstructured":"De Rycke L et al. (2003) Antinuclear antibodies following infliximab treatment inpatients with rheumatoid arthritis or spondyloarthropathy. Arthritis Rheum 48: 1015\u20131023","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0708_CR34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/01.bor.0000198007.73320.6e","volume":"18","author":"B Haraoui","year":"2006","unstructured":"Haraoui B et al. (2006) Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr Opin Rheumatology 18: 96\u2013100","journal-title":"Curr Opin Rheumatology"},{"key":"BFncprheum0708_CR35","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0140-6736(02)07714-0","volume":"359","author":"N Shakoor","year":"2002","unstructured":"Shakoor N et al. (2002) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359: 579\u2013580","journal-title":"Lancet"},{"key":"BFncprheum0708_CR36","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1002\/art.21190","volume":"52","author":"L De Rycke","year":"2005","unstructured":"De Rycke L et al. (2005) Infliximab, but not etanercept, induced IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 52: 2192\u20132201","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0708_CR37","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1136\/ard.2004.024182","volume":"64","author":"C Eriksson","year":"2005","unstructured":"Eriksson C et al. (2005) Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 64: 403\u2013407","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0708_CR38","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1177\/0961203306071703","volume":"15","author":"M DeBandt","year":"2006","unstructured":"DeBandt M (2006) Lessons for lupus from tumor necrosis factor blockade. Lupus 15: 762\u2013767","journal-title":"Lupus"},{"key":"BFncprheum0708_CR39","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1136\/ard.2003.018093","volume":"63","author":"T Jonsdottir","year":"2004","unstructured":"Jonsdottir T et al. (2004) Treatment with tumor necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 63: 1075\u20131078","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0708_CR40","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1136\/ard.61.11.1031","volume":"61","author":"AP Cairns","year":"1999","unstructured":"Cairns AP et al. (1999) New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 61: 1031\u20131032","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0708_CR41","doi-asserted-by":"publisher","first-page":"634","DOI":"10.7326\/0003-4819-131-8-199910190-00031","volume":"131","author":"PH Brion","year":"1999","unstructured":"Brion PH et al. (1999) Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med 131: 634","journal-title":"Ann Intern Med"},{"key":"BFncprheum0708_CR42","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s10067-002-0654-5","volume":"22","author":"M DeBandt","year":"2003","unstructured":"DeBandt M et al. (2003) Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 22: 56\u201361","journal-title":"Clin Rheumatol"},{"key":"BFncprheum0708_CR43","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S0140-6736(02)09800-8","volume":"360","author":"AK Mohan","year":"2002","unstructured":"Mohan AK et al. (2002) Drug-induced systemic lupus erythematosus and TNF-\u03b1 blockers. Lancet 360: 646","journal-title":"Lancet"},{"key":"BFncprheum0708_CR44","first-page":"740","volume":"32","author":"A Mor","year":"2005","unstructured":"Mor A et al. (2005) Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol 32: 740\u2013743","journal-title":"J Rheumatol"},{"key":"BFncprheum0708_CR45","doi-asserted-by":"crossref","unstructured":"Stokes et al. (2005) Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 20: 1400\u20131406","DOI":"10.1093\/ndt\/gfh832"},{"key":"BFncprheum0708_CR46","first-page":"1955","volume":"31","author":"N Mohan","year":"2004","unstructured":"Mohan N et al. (2004) Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 31: 1955\u20131958","journal-title":"J Rheumatol"},{"key":"BFncprheum0708_CR47","doi-asserted-by":"publisher","first-page":"R545","DOI":"10.1186\/ar1715","volume":"7","author":"M De Bandt","year":"2005","unstructured":"De Bandt M et al. (2005) Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 7: R545\u2013551","journal-title":"Arthritis Res Ther"},{"key":"BFncprheum0708_CR48","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","volume":"86","author":"M Ramos-Casals","year":"2007","unstructured":"Ramos-Casals M et al. (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86: 242\u2013251","journal-title":"Medicine (Baltimore)"},{"key":"BFncprheum0708_CR49","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1136\/ard.2005.043166","volume":"65","author":"MH Schiff","year":"2006","unstructured":"Schiff MH et al. (2006) Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65: 889\u2013894","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 4","key":"BFncprheum0708_CR50","doi-asserted-by":"crossref","first-page":"iv18","DOI":"10.1136\/ard.2005.042549","volume":"64","author":"JJ Cush","year":"2005","unstructured":"Cush JJ (2005) Biological drug use: US perspectives on indications and monitoring. Ann Rheum Dis 64 (Suppl 4): iv18\u201323","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0708_CR51","doi-asserted-by":"publisher","first-page":"178","DOI":"10.7326\/0003-4819-115-3-178","volume":"115","author":"LE R\u00f6nnblom","year":"1991","unstructured":"R\u00f6nnblom LE et al. (1991) Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 115: 178\u2013183","journal-title":"Ann Intern Med"},{"key":"BFncprheum0708_CR52","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/hep.1840100106","volume":"10","author":"WJ Mayet","year":"1989","unstructured":"Mayet WJ et al. (1989) Treatment of chronic type B hepatitis with recombinant alpha-interferon induced autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 10: 24\u201328","journal-title":"Hepatology"},{"key":"BFncprheum0708_CR53","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJM198806163182401","volume":"318","author":"MB Atkins","year":"1988","unstructured":"Atkins MB et al. (1988) Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318: 1557\u20131563","journal-title":"N Engl J Med"},{"key":"BFncprheum0708_CR54","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1365-2249.1992.tb05852.x","volume":"90","author":"H Gisslinger","year":"1992","unstructured":"Gisslinger H et al. (1992) Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin Exp Immunol 90: 363\u2013367","journal-title":"Clin Exp Immunol"},{"key":"BFncprheum0708_CR55","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1002\/1097-0142(19900515)65:10<2237::AID-CNCR2820651013>3.0.CO;2-5","volume":"65","author":"KC Conlon","year":"1990","unstructured":"Conlon KC et al. (1990) Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 65: 2237\u20132242","journal-title":"Cancer"},{"key":"BFncprheum0708_CR56","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/rheumatology\/33.8.787","volume":"33","author":"A Flores","year":"1994","unstructured":"Flores A et al. (1994) Systemic lupus erythematosus following interferon therapy. Br J Rheumatol 33: 787\u2013792","journal-title":"Br J Rheumatol"},{"key":"BFncprheum0708_CR57","first-page":"S121","volume":"10","author":"G Obermoser","year":"2001","unstructured":"Obermoser G et al. (2001) Lupus-like syndrome following interferon therapy in a patient with chronic myelogenous leukemia. Lupus 10: S121","journal-title":"Lupus"},{"key":"BFncprheum0708_CR58","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1056\/NEJMe058307","volume":"354","author":"H Koon","year":"2006","unstructured":"Koon H and Atkins M (2006) Autoimmunity and immunotherapy for cancer. N Engl J Med 354: 758\u2013760","journal-title":"N Engl J Med"},{"key":"BFncprheum0708_CR59","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/0002-9343(92)90789-E","volume":"92","author":"EM Massarotti","year":"1992","unstructured":"Massarotti EM et al. (1992) Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy. Am J Med 92: 693\u2013697","journal-title":"Am J Med"},{"key":"BFncprheum0708_CR60","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa053007","volume":"354","author":"H Gogas","year":"2006","unstructured":"Gogas H et al. (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354: 709\u2013718","journal-title":"N Engl J Med"},{"key":"BFncprheum0708_CR61","unstructured":"Lahita RG (Ed.; 1999) Systemic Lupus Erythematosus, edn 3. New York, NY: Academic Press"}],"container-title":["Nature Clinical Practice Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0708.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0708","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0708.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T20:33:49Z","timestamp":1737837229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncprheum0708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,16]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["BFncprheum0708"],"URL":"https:\/\/doi.org\/10.1038\/ncprheum0708","relation":{},"ISSN":["1745-8382","1745-8390"],"issn-type":[{"value":"1745-8382","type":"print"},{"value":"1745-8390","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,16]]}}}